GSK

Ahead Together

We unite science, technology and talent to get ahead of disease together. We are committed to doing the right thing and we aim to positively impact the health of 2.5 billion people by the end of 2030. We’ll do this by bringing together outstanding people and doing work that matters in an inclusive environment, so we can make an impact on a global scale.

We prevent and treat disease with vaccines, specialty and general medicines.  We focus on science of the immune system, human genetics and advanced technologies investing in 4 core therapeutic areas and future opportunities to impact health at scale. We operate responsibly for all our stakeholders by prioritising Innovation, Performance and Trust.

We are ambitious for patients to deliver what matters better and faster. 

We are accountable for impact  with clear ownership  and support to succeed. 

We do the right thing with integrity and care because people count on us

What we do

• We develop cancer medicines with life-changing potential for patients including ovarian cancer, endometrial cancer and multiple myeloma.
• We have developed a new monoclonal antibody treatment for COVID-19. Monoclonal antibodies work in a similar way to the human immune system and can help people who do not have a strong natural immune response to a virus.
• We delivered three major product approvals in 2021 for endometrial cancer, COVID-19 and HIV. 
• Our vaccines portfolio is the broadest in the industry, helping protect people from meningitis, shingles, flu, polio, measles and many more.
• We have three marketed cancer therapies, with a further nine assets in development.
• We're focusing on antimicrobial resistance and drug-resistant infections with 28 R&D projects targeting priority pathogens including those deemed ‘critical’ and ‘urgent’ by the World Health Organization.  
• Two million of our vaccines are administered every day, and 40% of the world’s children receive a GSK vaccine each year.
• Since 2017, we’ve delivered 13 major approvals and more than doubled the number of potential new vaccines and medicines we have in Phase 3 and registration, to 23.
• Our ground-breaking malaria vaccine is the first and only vaccine shown in long-term clinical trials to reduce malaria in children.

Our portfolio

Vaccines

Vaccines help protect people from infectious diseases at every stage of life. Our vaccines portfolio is the broadest in the industry, helping protect people from meningitis, shingles, flu, polio, measles and many more. Today, two million doses of our vaccines are administered daily, and 4 in 10 of the world’s children receive a GSK jab each year. We use diverse platform technologies from adjuvants that improve vaccine effectiveness through to mRNA technology. These are at the heart of our pipeline differentiation.

Specialty medicines

Specialty medicines are prescribed by specialist healthcare practitioners. For GSK this includes our cancer medicines that have life-changing potential for patients. We’re also developing medicines for immune-mediated conditions, including the first new medicine for the chronic autoimmune condition lupus in over 50 years.

We are global leaders in developing medicines for HIV. Having pioneered the first HIV treatments in the 1980s, our goal now is to limit the impact of HIV on people’s lives by treating, preventing and ultimately curing it. We focus on life-changing cancer medicines and novel treatments for other immune-mediated diseases.

General medicines

General medicines are usually prescribed in primary care or community settings by general healthcare practitioners. From inhaled medicines for asthma and COPD to antibiotics to medicines for skin diseases, we make life better for millions of people in over 112 countries. Every day, these medicines improve health and make life better for millions of people all over the world. For more than 50 years, we’ve helped millions of people with respiratory conditions to breathe more easily, including the first inhalers in 1969, and we remain the industry leader in respiratory science.

Our therapeutic areas

Infectious diseases

Almost half the vaccines and medicines in our pipeline address infectious diseases, helping protect people from diseases like meningitis, shingles, flu, polio, measles and many more.

HIV

Our long-acting HIV medicines have the potential to dramatically change people’s experience by giving them an alternative to daily medicine.

Oncology

We develop cancer medicines with life-changing potential for patients with ovarian cancer, endometrial cancer and multiple myeloma. We’ve accelerated this research and currently have three marketed therapies and a further nine assets in development.

Immunology

Our focus on the science of the immune system helps us develop vaccines and medicines for a range of immune-mediated conditions, including the first new medicine for the chronic autoimmune condition lupus in over 50 years.